RT Journal Article
SR Electronic
T1 Longitudinal proteomic profiling of high-risk patients with COVID-19 reveals markers of severity and predictors of fatal disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.05.20223289
DO 10.1101/2020.11.05.20223289
A1 Gisby, Jack
A1 Clarke, Candice L.
A1 Medjeral-Thomas, Nicholas
A1 Malik, Talat H.
A1 Papadaki, Artemis
A1 Mortimer, Paige M.
A1 Buang, Norzawani B.
A1 Lewis, Shanice
A1 Pereira, Marie
A1 Toulza, Frederic
A1 Fagnano, Ester
A1 Mawhin, Marie-Anne
A1 Dutton, Emma E.
A1 Tapeng, Lunnathaya
A1 Kirk, Paul
A1 Behmoaras, Jacques
A1 Sandhu, Eleanor
A1 McAdoo, Stephen P.
A1 Prendecki, Maria F.
A1 Pickering, Matthew C.
A1 Botto, Marina
A1 Willicombe, Michelle
A1 Thomas, David C.
A1 Peters, James E.
YR 2020
UL http://medrxiv.org/content/early/2020/11/06/2020.11.05.20223289.abstract
AB End-stage kidney disease (ESKD) patients are at high risk of severe COVID-19. We performed dense serial blood sampling in hospitalised and non-hospitalised ESKD patients with COVID-19 (n=256 samples from 55 patients) and used Olink immunoassays to measure 436 circulating proteins. Comparison to 51 non-infected ESKD patients revealed 221 proteins differentially expressed in COVID-19, of which 69.7% replicated in an independent cohort of 46 COVID-19 patients. 203 proteins were associated with clinical severity scores, including IL6, markers of monocyte recruitment (e.g. CCL2, CCL7), neutrophil activation (e.g proteinase-3) and epithelial injury (e.g. KRT19). Random Forests machine learning identified predictors of current or future severity such as KRT19, PARP1, PADI2, CCL7, and IL1RL1 (ST2). Survival analysis with joint models revealed 69 predictors of death including IL22RA1, CCL28, and the neutrophil-derived chemotaxin AZU1 (Azurocidin). Finally, longitudinal modelling with linear mixed models uncovered 32 proteins that display different temporal profiles in severe versus non-severe disease, including integrins and adhesion molecules. Our findings point to aberrant innate immune activation and leucocyte-endothelial interactions as central to the pathology of severe COVID-19. The data from this unique cohort of high-risk individuals provide a valuable resource for identifying drug targets in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was partly funded by Community Jameel and the Imperial Presidents Excellence Fund and by a UKRI-DHSC COVID-19 Rapid Response Rolling Call. We also acknowledge a contribution from UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC) and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. JEP is supported by UKRI Innovation Fellowship at Health Data Research UK. DCT is funded by a Stage 2 Wellcome-Beit Prize Clinical Research Career Development Fellowship. MCP is a Wellcome Trust Senior Fellow in Clinical Science. NMT and ES are supported by Wellcome Trust and Imperial College London Research Fellowships, and CLC by an Auchi Clinical Research Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study ethics were reviewed by the UK National Health Service (NHS) Health Research Authority (HRA) and Health and Care Research Wales (HCRW) Research Ethics Committee (reference 20/WA/0123: The impact of COVID-19 on patients with renal disease and immunosuppressed patients). Ethical approval was given. All participants (patients and controls) were recruited from the Imperial College Renal and Transplant Centre and its satellite dialysis units, London, and provided written informed consent prior to participation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull summary statistics are included in the Supplementary Tables. Individual-level proteomic and clinical phenotyping data are available as Source Data Files. Code is available in the following GitHub repository: https://github.com/jackgisby/longitudinal_olink_proteomics